JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

By News Health
2 months Ago

(MedPage Today) — CHICAGO — Treatment of giant cell arteritis (GCA) with the oral drug upadacitinib (Rinvoq) was durably effective when continued for 2 years, results from a phase III trial extension indicated.
Some 85% of patients remained…

Source link : https://www.medpagetoday.com/meetingcoverage/acr/118147

Author :

Publish date : 2025-10-26 21:12:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma

Doctors Call Health System’s Bluff on Noncompete Agreements

Emergency vs Referral Routes in Lung Cancer Care

Cosmology’s Great Debate began a century ago – and is still going

Couples-Based Cardiac Care Improves Healthy Behaviors

Secondary Cancers After NSCLC: What’s the Risk?